238 related articles for article (PubMed ID: 10898311)
1. Serum YKL-40 is increased in patients with hepatic fibrosis.
Johansen JS; Christoffersen P; Møller S; Price PA; Henriksen JH; Garbarsch C; Bendtsen F
J Hepatol; 2000 Jun; 32(6):911-20. PubMed ID: 10898311
[TBL] [Abstract][Full Text] [Related]
2. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis?
Johansen JS; Møller S; Price PA; Bendtsen F; Junge J; Garbarsch C; Henriksen JH
Scand J Gastroenterol; 1997 Jun; 32(6):582-90. PubMed ID: 9200292
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease.
Nøjgaard C; Johansen JS; Christensen E; Skovgaard LT; Price PA; Becker U;
J Hepatol; 2003 Aug; 39(2):179-86. PubMed ID: 12873813
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.
Saitou Y; Shiraki K; Yamanaka Y; Yamaguchi Y; Kawakita T; Yamamoto N; Sugimoto K; Murata K; Nakano T
World J Gastroenterol; 2005 Jan; 11(4):476-81. PubMed ID: 15641129
[TBL] [Abstract][Full Text] [Related]
5. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease.
Tran A; Benzaken S; Saint-Paul MC; Guzman-Granier E; Hastier P; Pradier C; Barjoan EM; Demuth N; Longo F; Rampal P
Eur J Gastroenterol Hepatol; 2000 Sep; 12(9):989-93. PubMed ID: 11007134
[TBL] [Abstract][Full Text] [Related]
6. Determination of serum levels of YKL-40 and hyaluronic acid in patients with hepatic fibrosis due to schistosomiasis japonica and appraisal of their clinical value.
Zheng M; Cai WM; Zhao JK; Zhu SM; Liu RH
Acta Trop; 2005; 96(2-3):148-52. PubMed ID: 16188216
[TBL] [Abstract][Full Text] [Related]
7. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis.
Rath T; Roderfeld M; Güler C; Wenzel C; Graf J; Beitinger F; Roeb E; Zachoval R
Scand J Gastroenterol; 2011 Nov; 46(11):1369-80. PubMed ID: 21905976
[TBL] [Abstract][Full Text] [Related]
8. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C.
Pungpapong S; Nunes DP; Krishna M; Nakhleh R; Chambers K; Ghabril M; Dickson RC; Hughes CB; Steers J; Nguyen JH; Keaveny AP
Liver Transpl; 2008 Sep; 14(9):1294-302. PubMed ID: 18756457
[TBL] [Abstract][Full Text] [Related]
9. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C.
Fontana RJ; Goodman ZD; Dienstag JL; Bonkovsky HL; Naishadham D; Sterling RK; Su GL; Ghosh M; Wright EC;
Hepatology; 2008 Mar; 47(3):789-98. PubMed ID: 18175357
[TBL] [Abstract][Full Text] [Related]
10. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection.
Schiavon LL; Carvalho-Filho RJ; Narciso-Schiavon JL; Medina-Pestana JO; Lanzoni VP; Ferraz ML; Silva AE
Scand J Gastroenterol; 2010 May; 45(5):615-22. PubMed ID: 20163287
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C.
Mehta P; Ploutz-Snyder R; Nandi J; Rawlins SR; Sanderson SO; Levine RA
Am J Gastroenterol; 2008 Apr; 103(4):928-36. PubMed ID: 18371145
[TBL] [Abstract][Full Text] [Related]
12. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection.
Berres ML; Papen S; Pauels K; Schmitz P; Zaldivar MM; Hellerbrand C; Mueller T; Berg T; Weiskirchen R; Trautwein C; Wasmuth HE
J Hepatol; 2009 Feb; 50(2):370-6. PubMed ID: 19070929
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection.
Schiavon LL; Narciso-Schiavon JL; Carvalho Filho RJ; Sampaio JP; Medina-Pestana JO; Lanzoni VP; Silva AE; Ferraz ML
J Viral Hepat; 2008 Sep; 15(9):666-74. PubMed ID: 18482283
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C.
Esmat G; Metwally M; Zalata KR; Gadalla S; Abdel-Hamid M; Abouzied A; Shaheen AA; El-Raziky M; Khatab H; El-Kafrawy S; Mikhail N; Magder LS; Afdhal NH; Strickland GT
J Hepatol; 2007 Apr; 46(4):620-7. PubMed ID: 17316875
[TBL] [Abstract][Full Text] [Related]
15. Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience.
Lee CK; Perez-Atayde AR; Mitchell PD; Raza R; Afdhal NH; Jonas MM
J Pediatr; 2013 Oct; 163(4):1058-64.e2. PubMed ID: 23759423
[TBL] [Abstract][Full Text] [Related]
16. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis.
Parés A; Deulofeu R; Giménez A; Caballería L; Bruguera M; Caballería J; Ballesta AM; Rodés J
Hepatology; 1996 Dec; 24(6):1399-403. PubMed ID: 8938169
[TBL] [Abstract][Full Text] [Related]
17. Serum YKL-40 in young patients with β-thalassemia major: Relation to hepatitis C virus infection, liver stiffness by transient elastography and cardiovascular complications.
El-Asrar MA; Elbarbary NS; Ismail EA; Elshenity AM
Blood Cells Mol Dis; 2016 Jan; 56(1):1-8. PubMed ID: 26603717
[TBL] [Abstract][Full Text] [Related]
18. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease.
Kumagai E; Mano Y; Yoshio S; Shoji H; Sugiyama M; Korenaga M; Ishida T; Arai T; Itokawa N; Atsukawa M; Hyogo H; Chayama K; Ohashi T; Ito K; Yoneda M; Kawaguchi T; Torimura T; Nozaki Y; Watanabe S; Mizokami M; Kanto T
Sci Rep; 2016 Oct; 6():35282. PubMed ID: 27739482
[TBL] [Abstract][Full Text] [Related]
19. YKL-40 in giant cells and macrophages from patients with giant cell arteritis.
Johansen JS; Baslund B; Garbarsch C; Hansen M; Stoltenberg M; Lorenzen I; Price PA
Arthritis Rheum; 1999 Dec; 42(12):2624-30. PubMed ID: 10616010
[TBL] [Abstract][Full Text] [Related]
20. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease.
Vind I; Johansen JS; Price PA; Munkholm P
Scand J Gastroenterol; 2003 Jun; 38(6):599-605. PubMed ID: 12825867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
